- Previous Close
11,998.00 - Open
12,074.00 - Bid 11,844.00 x --
- Ask 11,846.00 x --
- Day's Range
11,784.00 - 12,082.00 - 52 Week Range
9,670.00 - 13,336.00 - Volume
210,351 - Avg. Volume
380,750 - Market Cap (intraday)
183.508B - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
3,411.53 - EPS (TTM)
3.47 - Earnings Date Apr 29, 2025
- Forward Dividend & Yield 2.46 (2.05%)
- Ex-Dividend Date Feb 20, 2025
- 1y Target Est
--
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
www.astrazeneca.com94,300
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AZNL.XC
View MorePerformance Overview: AZNL.XC
Trailing total returns as of 3/17/2025, which may include dividends or other distributions. Benchmark is FTSE 100 .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AZNL.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AZNL.XC
View MoreValuation Measures
Market Cap
185.93B
Enterprise Value
204.91B
Trailing P/E
34.54
Forward P/E
17.48
PEG Ratio (5yr expected)
0.93
Price/Sales (ttm)
4.49
Price/Book (mrq)
6.16
Enterprise Value/Revenue
4.91
Enterprise Value/EBITDA
17.20
Financial Highlights
Profitability and Income Statement
Profit Margin
13.01%
Return on Assets (ttm)
7.88%
Return on Equity (ttm)
17.59%
Revenue (ttm)
54.07B
Net Income Avi to Common (ttm)
7.03B
Diluted EPS (ttm)
3.47
Balance Sheet and Cash Flow
Total Cash (mrq)
5.53B
Total Debt/Equity (mrq)
74.53%
Levered Free Cash Flow (ttm)
8.46B